GLP-1 Peptide Comparison 2026: Semaglutide vs Tirzepatide vs Retatrutide
Three GLP-1-class compounds dominate research interest in 2026: semaglutide, tirzepatide, and retatrutide. They share a core mechanism — activation of the GLP-1 receptor — but differ significantly in receptor selectivity, clinical trial outcomes, approval status, and pricing. This guide breaks down what separates them and how they compare across the criteria that matter most for research decisions.
How GLP-1 Receptor Agonists Work
All three compounds activate the glucagon-like peptide-1 (GLP-1) receptor, a G-protein-coupled receptor expressed in the pancreas, hypothalamus, brainstem, and gut. GLP-1 receptor activation produces:
- Increased insulin secretion (glucose-dependent — only when blood glucose is elevated)
- Reduced glucagon release (decreasing hepatic glucose output)
- Slowed gastric emptying (the primary mechanism behind satiety and reduced caloric intake)
- Central appetite suppression (direct hypothalamic and brainstem effects)
Where the three compounds diverge is in what other receptors they also target — a critical difference that shapes both efficacy and side effects.
Semaglutide: The Established Standard
Type: GLP-1 receptor agonist (mono-agonist) Developer: Novo Nordisk FDA Status: Approved as Ozempic (type 2 diabetes), Wegovy (obesity), and Rybelsus (oral, diabetes)
Mechanism
Semaglutide selectively activates the GLP-1 receptor. It was engineered with a fatty acid chain that binds to albumin in the bloodstream, extending its half-life from minutes (native GLP-1) to approximately 7 days. This allows once-weekly subcutaneous dosing.
Efficacy Data
The STEP clinical trial program (2021) established semaglutide 2.4mg/week as a weight loss intervention:
- STEP 1: 14.9% mean body weight reduction at 68 weeks (versus 2.4% placebo)
- STEP 2 (T2D population): 9.6% mean body weight reduction
- STEP 3 (with behavioral intervention): 16.0% mean body weight reduction
The SELECT trial (2023) showed cardiovascular benefits independent of weight loss — a landmark finding that significantly broadened semaglutide's research profile beyond metabolic outcomes.
Research Profile
Semaglutide has the largest and most well-characterized clinical trial dataset of the three compounds. Its cardiovascular outcomes data, cancer-risk studies, and Alzheimer's disease research (EVOKE trial) make it the most studied GLP-1 agent to date. This depth of evidence is both an advantage (the most known) and a limitation (the ceiling on potential outcomes is better understood).
Tirzepatide: The Dual Agonist Advantage
Type: GLP-1 / GIP dual receptor agonist Developer: Eli Lilly FDA Status: Approved as Mounjaro (type 2 diabetes) and Zepbound (obesity)
Mechanism
Tirzepatide activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP receptor activation adds:
- Enhanced insulin secretion (additive with GLP-1 signaling)
- GIP's adipocyte effects — GIP receptors on fat cells appear to directly modulate fat storage/release
- Potentially superior lean mass preservation compared to GLP-1 monotherapy (a mechanistic hypothesis with growing supporting data)
Half-life is approximately 5 days, enabling once-weekly dosing.
Efficacy Data
The SURMOUNT clinical trial program showed notably higher weight loss than semaglutide Phase 3 data:
- SURMOUNT-1: 20.9% mean body weight reduction at 72 weeks (15mg dose)
- SURMOUNT-2 (T2D population): 15.7% mean body weight reduction
- SURPASS-2 (head-to-head vs semaglutide 1mg for diabetes): Superior A1C reduction and weight loss with tirzepatide
Tirzepatide consistently outperforms semaglutide in direct-comparator and parallel-design studies in both weight loss magnitude and glycemic control.
Research Profile
Tirzepatide's dual agonism appears to produce meaningful advantages over GLP-1 monotherapy. The GIP receptor contribution to fat metabolism and potential lean mass preservation is an active area of mechanistic research. The compound's Phase 3 data is the most robust of the three for weight loss magnitude among approved drugs. Cardiovascular outcomes data (SURMOUNT-MMO) is expected and will be a key data point going forward.
Retatrutide: The Triple Agonist Frontier
Type: GLP-1 / GIP / Glucagon triple receptor agonist Developer: Eli Lilly FDA Status: Not approved — Phase 3 (TRIUMPH program) underway as of 2026
Mechanism
Retatrutide adds glucagon receptor activation to the GLP-1 and GIP agonism of tirzepatide. The glucagon receptor component:
- Increases energy expenditure — glucagon receptor signaling in the liver and adipose tissue directly promotes fat oxidation, unlike GLP-1 which primarily reduces intake
- Addresses metabolism from multiple angles — intake reduction (GLP-1), enhanced insulin response (GIP + GLP-1), and active energy expenditure (glucagon)
This triple mechanism is why retatrutide produced the highest weight loss numbers in Phase 2 data. Half-life is approximately 6 days.
Efficacy Data
Phase 2 data published in the New England Journal of Medicine (Jastreboff et al., 2023):
- 24.2% mean body weight reduction at 48 weeks (highest dose cohort, 12mg)
- Consistently outperformed both semaglutide and tirzepatide in cross-trial comparison at equivalent timepoints
- Phase 3 TRIUMPH program underway — TRIUMPH-1 (obesity), TRIUMPH-CVOT (cardiovascular), and bone/lean mass substudies
Research Profile
Retatrutide's Phase 2 data is the most compelling efficacy signal in the GLP-1 space to date. The mechanistic rationale for glucagon receptor addition is well-supported. Key open questions:
- Whether Phase 2 efficacy holds in broader Phase 3 populations
- Long-term glucagon receptor agonism effects on bone density and lean mass
- Cardiovascular outcomes data (not yet available)
- Regulatory submission timeline — not expected before late 2026 at earliest
Side-by-Side Comparison
| Semaglutide | Tirzepatide | Retatrutide | |
|---|---|---|---|
| Receptor targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| FDA approval | Yes (Ozempic/Wegovy) | Yes (Mounjaro/Zepbound) | No (Phase 3) |
| Phase 3 weight loss | ~15% | ~21% | ~24% (Phase 2) |
| Half-life | ~7 days | ~5 days | ~6 days |
| Dosing frequency | Weekly | Weekly | Weekly |
| GI side effects | Moderate | Moderate | Higher (triple agonism) |
| Lean mass concern | Moderate | Lower | Unknown (under study) |
| CV outcomes data | Yes (SELECT) | Pending | Pending |
| Evidence depth | Deepest | Deep | Early (Phase 2) |
| Oral option | Yes (Rybelsus, Wegovy pill) | Yes (Foundayo, 2026) | No |
Pricing Comparison: Research-Grade in 2026
All three compounds are available as research-grade peptides from verified US suppliers. Pricing varies by supplier, vial size, and product purity.
Approximate per-mg pricing ranges (in-stock, third-party COA suppliers):
- Semaglutide: $4–$12/mg (most competitive — highest supply volume)
- Tirzepatide: $5–$14/mg (strong competition, widely available)
- Retatrutide: $8–$22/mg (lower supply volume; higher synthesis cost)
For current real-time pricing, use the live comparison pages:
Which Compound to Research?
If depth of evidence matters most: Semaglutide has by far the largest clinical dataset — cardiovascular outcomes, cancer research, neurological studies, and the most well-characterized safety profile of the three.
If efficacy data in weight loss is the primary criterion: Tirzepatide's Phase 3 data shows consistently higher weight loss than semaglutide with an approved safety profile. The GIP receptor addition appears to provide real mechanistic advantages.
If you're studying the frontier of GLP-1 pharmacology: Retatrutide's Phase 2 data shows the highest weight loss signal of any compound in this class to date. The triple agonism mechanism raises research questions that won't be answered until Phase 3 data is published — making it the highest-information but highest-uncertainty option.
Regulatory Considerations
Semaglutide and tirzepatide have been removed from the FDA drug shortage list (semaglutide in October 2024, tirzepatide in early 2025), ending the legal basis for 503A/503B compounding. Research-grade peptide suppliers operate under a legally distinct category from compounding pharmacies and are not subject to the same shortage-list rules — but FDA enforcement attention on the broader peptide space has increased in 2025–2026.
Retatrutide has no FDA approval pathway yet. All research-grade retatrutide is supplied for laboratory research purposes only.
All compounds are sold by listed suppliers for research purposes only and are not intended for human use, food, or drug applications. This content is informational and does not constitute medical advice. Bestpepprices.com does not sell compounds and is not compensated by any supplier for rankings or coverage.
Compare Semaglutide prices → | Compare Tirzepatide prices → | Compare Retatrutide prices →
Compare live prices across 60+ verified research peptide suppliers